The long-term success of national efforts to reduce breast cancer incidence and mortality rests in part on the ability of Breast Cancer SPORE programs to attract and build the translational research careers of talented young faculty and to redirect senior faculty to breast cancer research. For the past fourteen years, the UNC Breast Cancer SPORE has effectively used career development funds to promote the breast cancer research careers of selected investigators. Participants in the SPORE career development program (CDP) have contributed to the national breast cancer effort and established long-term careers as translational breast cancer researchers. Their contributions include published research, funded grants focused on breast cancer, participation in collaborative breast cancer research and leadership within the SPORE program itself. CDP participants have become an integral part of the UNC Breast Cancer SPORE. Seven CDP alumni (Drs. Carey, Dees, Klauber-DeMore, Livasy, Millikan, Perou Sartor) serve as co-leaders on the projects and core facilities in this application;each of the five proposed SPORE projects has a CDP alum as co-leader. As a result of the Breast Cancer SPORE, all seven investigators are now firmly established as translational breast cancer researchers, each with distinct interests, collaborations, and honors. Over the next five years, the UNC Breast Cancer SPORE will continue to promote and develop careers in translational breast cancer research. We request SPORE support of $50,000 per year to combine with $50,000 in institutional funds to provide $100,000 total in flexible funds for career development. The SPORE will use these funds in three categories: 1) to help recruit and develop junior faculty with translational breast cancer research programs;2) to provide salary support for senior faculty at UNC developing breast cancer research interests or projects;and 3) to attract more senior faculty from other institutions by offering funded leaves of three to twelve months to develop or enhance a breast cancer research focus. For Year 15, the SPORE proposes to support the development of two junior faculty interested in translational breast cancer research: Pilar Blancafort, PhD and Jeffrey Peppercorn, MD. CDP candidates will take advantage of the research and training opportunities available at UNC through the SPORE, the Cancer Center, and the University at large. Working with pre-, postdoctoral, and faculty training programs in the clinical, basic and population sciences, the UNC Breast Cancer SPORE offers unique development opportunities. Fellows and junior faculty can obtain world-class mentoring to fine tune career directions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-18
Application #
8135450
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
18
Fiscal Year
2010
Total Cost
$70,516
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications